Skip to main content
Toggle menu

Search the website

Openprescribing Summer 2024 Newsletter

Posted:
Written by:
Categories:

You can sign up for email versions of this newsletter here.

Sign up for our free OpenPrescribing webinars

Webinar Image

Over the next few months, we’re going to be hosting a series of webinars to showcase the ins and outs of OpenPrescribing. They’ll cover the main features of OpenPrescribing, including the measures we provide and details of how to conduct your own analyses. We will also explore additional OpenPrescribing tools and provide practical tips to help you get the most out of OpenPrescribing.

We’ll be running different sessions for different groups, so whether you work in healthcare, or you’re simply interested in understanding how to use OpenPrescribing, there will be a session that suits you.

See this page to book your spot.

Planned removal of STAR-PUs from OpenPrescribing

Thank you to all those who have sent in comments about STAR-PUs following recent mentions in our newsletter and blog. Based on the feedback we have received so far, the majority of our users seem to be in favour of removing STAR-PUs as a denominator from OpenPrescribing. We therefore plan to gradually phase out STAR-PUs as a denominator in measures and as an option on the analyse page over the coming months.

💬 But it’s not too late to let us know your thoughts! Please tell us what you think about this topic by emailing us at bennett@phc.ox.ac.uk or posting on X at @OpenPrescribing. Do you still use STAR-PUs? How confident do you feel about their validity? What alternatives do you think are better?

Excess quantity of pens measure updated

Following the recent launch of tirzepatide in a multidose pen formulation, we have updated our excess quantity of pens measure. There have been some reports that prescribers are requesting four multidose pens per month in error (each multidose pen should last 4 weeks). This is unlikely to be required and likely to be caused by the dose and quantity being confused on a picking list. Some areas continue to prescribe high levels of excess pens despite an ongoing national shortage of these products.

Price Concessions Updates

Following recent changes to discount deduction applied to pharmacy contractors, we have updated our Price Concessions calculations to reflect the new arrangements. You can read more about what we’ve changed on our recent blog post.

We have also recently fixed an issue that underestimated the impact of price concessions for mometasone nasal spray.

OpenPrescribing relies on the English Prescribing Data published by NHS BSA. This data provides details on both the items and quantities of prescriptions. “Items” refers to the number of prescriptions issued. “Quantity” is more complex as it depends on the formulation of the product. Generally, for products that contain a specified number of doses, such as nasal sprays, the quantity corresponds to the number of doses contained in the product. However, we have found that mometasone nasal spray is an exception to this, where “quantity” refers to the number of whole packs (each containing 140 doses).

We rolled out a fix to manually correct for this, and the tool has been retrospectively adjusted to reflect the change.

Lidocaine plaster reduction strategies

In a recent guest blog, Molly Mattsson from RCSI University of Medicine and Health Sciences in Dublin, describes a collaboration with the Bennett Institute for Applied Data Science, which compared the effects of lidocaine plaster prescribing reduction strategies in England and Ireland.

OpenSAFELY News

Since the start of the pandemic, much of the OpenPrescribing team have been building and researching in our powerful new OpenSAFELY platform for COVID-19 related research and service monitoring. You can read all our outputs on the website and our new OpenSAFELY reports website, but we think the following recent research publications will be of interest:

We also invite you to join us for our 2nd Annual OpenSAFELY Community Symposium!